Table 5.

Viability propidium monoazide (PMA)xx RTqPCR assay of HuNoV GII present in artificially contaminated saliva and in the saliva of one patient.

Sample	Treatment	PMA	HuNoV RNA Log Genome Copies/mL	Log Reduction *
Artificially contaminated saliva	Untreated	-	6.72 ± 0.01	0.03
		+	6.69 ± 0.01
	5 min at 95 °C	-	2.91 ± 0.03	0.97
		+	1.94 ± 0.47
Patient	Untreated	-	3.45	0.30
		+	3.15

* Reduction in titers obtained between samples before and after viability pretreatment.